Takeda Pharma to restructure after annual profit slump

Japan's Takeda Pharmaceutical (4502.T) announced a restructuring on Thursday after annual profit slid by more than half following the loss of patent protection of major sellers.
Japan's biggest drugmaker said it will incur restructuring costs of about 140 billion yen ($899 million) this fiscal year as part of a plan to optimise its workforce, cut costs and strengthen technology.